Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leila Amini

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Scientific Reports|November 12, 2020
The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantationSharon Bajda, Arturo Blazquez-Navarro, Björn Samans, et al.
Kidney International|September 14, 2022
In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorderConstantin J Thieme, Malissa Schulz, Patrizia Wehler, et al.
Molecular Therapy. Methods & Clinical Development|March 7, 2022
Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patientsLena Peter, Désirée Jacqueline Wendering, Stephan Schlickeiser, et al.
Science Translational Medicine|January 14, 2021
The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancerTino Vollmer, Stephan Schlickeiser, Leila Amini, et al.
Nature Communications|October 13, 2025
HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation modelOliver McCallion, Weijie Du, Viktor Glaser, et al.
Leukemia & Lymphoma|November 4, 2014
Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemiaJaspal Kaeda, Frauke Ringel, Christian Oberender, et al.
BMJ (Clinical Research Ed.)|October 22, 2020
Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trialAndy Roemhild, Natalie Maureen Otto, Guido Moll, et al.
Molecular Therapy. Methods & Clinical Development|May 16, 2022
Pharmacological interventions enhance virus-free generation of <i>TRAC</i>-replaced CAR T cellsJonas Kath, Weijie Du, Alina Pruene, et al.
Science Advances|September 4, 2024
Effector memory-type regulatory T cells display phenotypic and functional instabilityDésirée Jacqueline Wendering, Leila Amini, Stephan Schlickeiser, et al.
Molecular Therapy. Advances|May 18, 2026
Clinical development of tacrolimus-resistant regulatory T cells to enable simultaneous immunosuppression and immune regulationGhazaleh Zarrinrad, Lisa-Marie Burkhardt, Claudia Beltran-Mestres, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Scientific Reports|November 12, 2020
The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantationSharon Bajda, Arturo Blazquez-Navarro, Björn Samans, et al.
Kidney International|September 14, 2022
In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorderConstantin J Thieme, Malissa Schulz, Patrizia Wehler, et al.
Molecular Therapy. Methods & Clinical Development|March 7, 2022
Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patientsLena Peter, Désirée Jacqueline Wendering, Stephan Schlickeiser, et al.
Science Translational Medicine|January 14, 2021
The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancerTino Vollmer, Stephan Schlickeiser, Leila Amini, et al.
Nature Communications|October 13, 2025
HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation modelOliver McCallion, Weijie Du, Viktor Glaser, et al.
Leukemia & Lymphoma|November 4, 2014
Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemiaJaspal Kaeda, Frauke Ringel, Christian Oberender, et al.
BMJ (Clinical Research Ed.)|October 22, 2020
Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trialAndy Roemhild, Natalie Maureen Otto, Guido Moll, et al.
Molecular Therapy. Methods & Clinical Development|May 16, 2022
Pharmacological interventions enhance virus-free generation of <i>TRAC</i>-replaced CAR T cellsJonas Kath, Weijie Du, Alina Pruene, et al.
Science Advances|September 4, 2024
Effector memory-type regulatory T cells display phenotypic and functional instabilityDésirée Jacqueline Wendering, Leila Amini, Stephan Schlickeiser, et al.
Molecular Therapy. Advances|May 18, 2026
Clinical development of tacrolimus-resistant regulatory T cells to enable simultaneous immunosuppression and immune regulationGhazaleh Zarrinrad, Lisa-Marie Burkhardt, Claudia Beltran-Mestres, et al.
Pageof 7